As tumor cells exhibit aberrant glycan signatures (35) and CLRs are crucial for DCs to shape and polarize immune responses (36, 37), we wondered if abnormal glycosylation of tumor surface glycoproteins and glycolipids could modulate DC activity through CLR signaling and subsequently subvert anti-tumor immune responses in the context of melanoma. The gene discussed is LARS1; the disease is neoplasm.